
Co-Diagnostics, Inc. (NASDAQ:CODX) shares plunged over 50% on Tuesday after the company announced a $7 million direct offering and a new Saudi-based joint venture.
The selloff suggested investors were more focused on the prospect of near-term dilution than the company's longer-term global expansion plans.